Stryker Corporation $SYK Stock: Tectonic Advisors LLC Increases Holdings

Tectonic Advisors LLC grew its position in Stryker Corporation (NYSE:SYK) by 69.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,109 shares of the medical technology company’s stock after purchasing an additional 1,679 shares during the quarter. Tectonic Advisors LLC’s holdings in Stryker were worth $1,132,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Amundi grew its position in shares of Stryker by 18.3% in the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after purchasing an additional 192,447 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Stryker by 8.2% in the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after purchasing an additional 65,333 shares during the period. Veritas Asset Management LLP bought a new position in shares of Stryker in the second quarter worth about $168,057,000. Bank of America Corp DE bought a new position in shares of Stryker in the second quarter worth about $1,404,284,000. Finally, Rakuten Investment Management Inc. acquired a new position in shares of Stryker during the 2nd quarter worth about $18,646,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SYK shares. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Canaccord Genuity Group lowered their target price on Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a report on Friday, September 18th. TD Cowen dropped their price target on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Citigroup dropped their price target on Stryker from $399.00 to $360.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Finally, UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Insider Activity at Stryker

In other Stryker news, Director Ronda Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last three months. Company insiders own 4.60% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $307.65 on Friday. The firm’s 50-day moving average is $295.23 and its 200-day moving average is $311.93. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a market cap of $118.01 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the business earned $3.13 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.